



Matthias Friedrich

Contact

Matthias Friedrich

Publications (15)

Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2023; 58:678–691.

Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. *Aliment Pharmacol Ther* 2022; 57:103–116.

Schnitzler F, Friedrich M, Angelberger M, Diegelmann J, Stallhofer J, Wolf C, Dütschler J, Truniger S, Olszak T, Beigel F, Tillack C, Lohse P, Brand S. Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery. *PloS one* 2020; 15:e0236421.

Stallhofer J, Beigel F, Schnitzler F, Tillack-Schreiber C, Glas J, Lohse P, Wetzke M, Konrad-Zerna A, Friedrich M, Brand S. Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF- α and Modulated by IL23R Genotype Status. *Inflamm Bowel Dis* 2015; 21:2327–40.

Schnitzler F, Grüner N, Rust C, Guba M, Denk G, Zachoval R, Göke B, Tillack C, Beigel F, Olszak T, Angelberger M, Wolf C, Karbalai N, Habicht A, Fischereeder M, Schönermarck U, Stallhofer J, Friedrich M, Brand S. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. *PloS one* 2015; 10:e0135807.

Schnitzler F, Lohse P, Glas J, Göke B, Beigel F, Tillack C, Olszak T, Diegelmann J, Angelberger M, Stallhofer J, Wolf C, Friedrich M, Brand S. The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations. *PloS one* 2015; 10:e0116044.

Schnitzler F, Lohse P, Glas J, Göke B, Stallhofer J, Tillack C, Beigel F, Olszak T, Diegelmann J, Angelberger M, Wolf C, Friedrich M, Brand S. The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067. *PloS one* 2014; 9:e108503.

Friedrich M, Tillack C, Wollenberg A, Schaub J, Brand S. IL-36 γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. *Inflamm Bowel Dis* 2014; 20:1891–901.

Friedrich M, Diegelmann J, Beigel F, Brand S. IL-17A alone weakly affects the transcriptome of intestinal epithelial cells but strongly modulates the TNF- α -induced expression of inflammatory mediators and inflammatory bowel disease susceptibility genes. *Inflamm Bowel Dis* 2014; 20:1502–15.

Beigel F, Friedrich M, Probst C, Sotlar K, Göke B, Diegelmann J, Brand S. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. *PloS one* 2014; 9:e93498.

Tillack C, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schaubert J, Wollenberg A, Maier H, Wetzke M, Ehmann L, Friedrich M, Laubender R, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Brand S. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon- γ -expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. *Gut* 2013; 63:567-77.

Glas J, Czamara D, Diegelmann J, Göke B, Friedrich M, Steib C, Beigel F, Wetzke M, Tsekeri E, Olszak T, Fries C, Stallhofer J, Bues S, Seiderer J, Brand S. IRGM variants and susceptibility to inflammatory bowel disease in the German population. *PloS one* 2013; 8:e54338.

Glas J, Czamara D, Diegelmann J, Ochsenkühn T, Göke B, Wetzke M, Steib C, Stallhofer J, Beigel F, Friedrich M, Tillack C, Fries C, Olszak T, Wagner J, Seiderer J, Brand S. Analysis of IL12B gene variants in inflammatory bowel disease. *PloS one* 2012; 7:e34349.

Glas J, Czamara D, Diegelmann J, Karbalai N, Ochsenkühn T, Göke B, Steib C, Friedrich M, Stallhofer J, Tillack C, Beigel F, Wetzke M, Olszak T, Seiderer J, Wagner J, Brand S. PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background. *PloS one* 2012; 7:e33682.

Glas J, Czamara D, Diegelmann J, Friedrich M, Steib C, Beigel F, Olszak T, Tillack C, Fries C, Wetzke M, Bayrle C, Seiderer J, Brand S. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease. *PloS one* 2011; 6:e29309.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch